Aclaris Therapeutics, Inc. (ACRS) Gross margin 2017–2025
Aclaris Therapeutics, Inc. (ACRS) gross margin by fiscal year — reported gross profit divided by reported revenue.
73.3%FY2025 · since FY2017: 28.3% → 73.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 73.3% | -11.8 pp |
| FY2024 | 85.1% | -4.0 pp |
| FY2023 | 89.0% | +2.6 pp |
| FY2022 | 86.5% | +56.2 pp |
| FY2021 | 30.3% | +9.5 pp |
| FY2020 | 20.8% | +16.7 pp |
| FY2019 | 4.1% | -48.6 pp |
| FY2018 | 52.7% | +24.4 pp |
| FY2017 | 28.3% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More ACRS financial trends
ACRS RevenueACRS Net incomeACRS Net marginACRS Gross profitACRS Operating incomeACRS Operating marginACRS Operating cash flowACRS Free cash flowACRS Capital expendituresACRS Return on equityACRS Stock buybacksACRS Dividends paidACRS Total assetsACRS Total liabilitiesACRS Shareholders’ equityACRS overview →